Members of the canonical transient receptor potential (TRPC) subfamily of cation channels are candidates for capacitative and non-capacitative Ca 2؉ entry channels. When ectopically expressed in cell lines, TRPC3 can be activated by phospholipase C-mediated generation of diacylglycerol or by addition of synthetic diacylglycerols, independently of Ca 2؉ store depletion. Apart from this mode of regulation, little is known about other receptordependent signaling events that modulate TRPC3 activity. In the present study the role of tyrosine kinases in receptor-and diacylglycerol-dependent activation of TRPC3 was investigated. In HEK293 cells stably expressing TRPC3, pharmacological inhibition of tyrosine kinases, and specifically of Src kinases, abolished activation of TRPC3 by muscarinic receptor stimulation and by diacylglycerol. Channel regulation was lost following expression of a dominant-negative mutant of Src, or when TRPC3 was expressed in an Src-deficient cell line. In both instances, wild-type Src restored TRPC3 regulation. We conclude that Src plays an obligatory role in the mechanism for receptor and diacylglycerol activation of TRPC3.
Members of the canonical transient receptor potential (TRPC) subfamily of cation channels are candidates for capacitative and non-capacitative Ca 2؉ entry channels. When ectopically expressed in cell lines, TRPC3 can be activated by phospholipase C-mediated generation of diacylglycerol or by addition of synthetic diacylglycerols, independently of Ca 2؉ store depletion. Apart from this mode of regulation, little is known about other receptordependent signaling events that modulate TRPC3 activity. In the present study the role of tyrosine kinases in receptor-and diacylglycerol-dependent activation of TRPC3 was investigated. In HEK293 cells stably expressing TRPC3, pharmacological inhibition of tyrosine kinases, and specifically of Src kinases, abolished activation of TRPC3 by muscarinic receptor stimulation and by diacylglycerol. Channel regulation was lost following expression of a dominant-negative mutant of Src, or when TRPC3 was expressed in an Src-deficient cell line. In both instances, wild-type Src restored TRPC3 regulation. We conclude that Src plays an obligatory role in the mechanism for receptor and diacylglycerol activation of TRPC3.
In many types of cells, membrane receptors coupled to phospholipase C (PLC) 1 promote inositol 1,4,5-trisphosphate (IP 3 )-mediated release of Ca 2ϩ from endoplasmic reticulum and Ca 2ϩ entry across the plasma membrane through both capacitative or store-operated and non-capacitative calcium entry pathways (1) (2) (3) . Although the molecular identity of capacitative and noncapacitative calcium entry channels, as well as the signaling mechanisms involved, remain uncertain, mammalian homologues of the Drosophila melanogaster transient receptor potential (TRP) channel have been considered as potential candidates (4, 5) , particularly members of the canonical TRP (TRPC) subfamily (designated TRPC1 through TRPC7 (6) ). The human isoform of TRPC3, originally cloned by Zhu et al. (7) , has been shown in many heterologous expression systems to behave as a receptoractivated channel that can be activated also by exogenous application of diacylglycerols (DAGs) independently of store depletion.
In fact, DAG-induced activation of TRPC3 and its structural relatives TRPC6 and TRPC7 (8, 9) provides the likely mechanism of activation of these channels by phosphoinositide-specific PLClinked receptors, independently of IP 3 and store depletion. Apart from its regulation by DAG generated from PLC stimulation through either G-protein-coupled receptors (GPCRs) or receptor tyrosine kinases (RTKs), little is known about additional signaling pathways downstream of receptor-stimulation involved in activation of TRPC3. Stimulation of either of these receptor pathways results in rapid tyrosine phosphorylation of cellular proteins (10, 11) , and so in the present study we investigated whether tyrosine kinases might play a role in the signaling mechanism underlying receptor-and DAG-dependent activation of TRPC3. We found that inhibition of tyrosine kinase activity completely abrogated the ability of either GPCR stimulation or exogenous application of diacylglycerol to induce TRPC3 activation. The results indicate an obligatory requirement for functional Src kinase for TRPC3 activation, likely involving Src-dependent phosphorylation and/or recruitment of an as yet unidentified accessory protein. In addition, the results show that activation of the channels by diacylglycerol is unlikely to involve a direct action of diacylglycerol on the channels.
MATERIALS AND METHODS
Cell Culture, Transfection, and Measurement of Intracellular Calcium-Human embryonic kidney cells (HEK293) stably expressing the human TRPC3 (TRPC3-HEK293) with either the hemagglutinin (HA)-epitope (TRPC3-HA) or the green fluorescent protein (TRPC3-GFP) fused to its C terminus, were cultured as previously described (12, 13) . For transient transfections, either TRPC3-HA or TRPC3-GFP cells were grown in 6-well plates and transfected as indicated with 1 g of either wild-type Src (WT-Src, kindly provided by Dr. Thomas E. Smithgall, Department of Molecular Genetics and Biochemistry, School of Medicine, University of Pittsburgh, Pittsburgh, PA), a dominant-negative mutant of Src (DN-Src, kindly provided by Dr. Sara Courtneidge, Van Andel Research Institute, Grand Rapids, MI), a constitutively active form of avian Src (CA-Src, courtesy of Dr. John O'Bryan, NIEHS, National Institutes of Health (NIH), Research Triangle Park, NC) or the corresponding vector alone (pcDNA3) and EYFP-C1 (EYFP, 0.5 g; Clontech) as a transfection marker by using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. 24 h after transfection, cells were plated onto glass coverslips and an additional 24 h later used for calcium measurements. Real-time fluorescence measurements with coverslip-plated cells were performed as in Trebak et al. (14) . When only Ca 2ϩ was measured in a particular experiment, calibrated [Ca 2ϩ ] i values are reported (i.e. see Fig. 1 ). In most instances, when experiments involved measurement of Ba 2ϩ entry, fluorescence * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. ratios (fluorescence at 510 nm with excitation at 340 nm divided by that with excitation at 380 nm) are reported. The DT40 chicken B lymphocyte cell line and the mutant variant deficient in PLC␥-2 (PLC␥-KO) were kindly provided by Dr. Tomohiro Kurosaki (Department of Molecular Genetics, Kansai Medical University). DT40 cells culture, transfection, loading with the Ca 2ϩ indicator Fura-2, and ratiometric measurement of intracellular Ca 2ϩ were accomplished as described previously (15) . Transient transfections of the wild-type and PLC␥-KO DT40 cells were performed by electroporation, with either the human isoform of TRPC3 (100 g/ml TRPC3 into pcDNA3 vector, provided by Dr. Lutz Birnbaumer, NIEHS, NIH), the human M5 muscarinic receptor (50 g/ml, in pcDNA3), vector alone (pcDNA3, mock transfected cells), or a combination of them, along with EYFP (5 g) as marker for transfection. Cells were used for real-time fluorescence measurements 17-25 h post-transfection.
SYF or Ba 2ϩ entry were made using a two-tailed t test for two means, or analysis of variance for three or more means. When the analysis of variance was found to be significant at p Ͻ 0.05, it was followed by Tukey-Kramer multicomparison tests carried out using GraphPad InStat software. Summarized data are given as means Ϯ S.E.
Cell Lysis, Immunoprecipitation, and Immunoblotting-Wild-type and HA-TRPC3-expressing HEK293 cells were plated onto polylysine-coated 60-mm tissue culture dishes. After 24 h, cells were washed two times in HEPES-buffered physiological saline solution (HBSS, composition in mM: 140 NaCl, 4.7 KCl, 1 MgCl 2 , 2.0 CaCl 2 , 10 glucose, 10 HEPES, pH 7.4) and equilibrated in the same solution for 20 min at room temperature. Following treatment with either vehicle, carbachol (300 M), EGF (150 ng/ml), or OAG (1-oleoyl-2-acetyl-snglycerol, 100 M), the cells were washed twice with ice-cold phosphate-buffered saline (PBS) solution and lysed in lysis buffer containing: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.2% sodium deoxycholate, 1 mM Na 3 VO 4 , 1 mM sodium pyrophosphate, 20 mM ␤-glycerophosphate, 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml pepstatin, 4 g/ml leupeptin, 10 g/ml aprotinin. After 30-min incubation on ice with shaking, samples were centrifuged for 20 min at maximal speed in an Eppendorf microcentrifuge, and supernatants were used for immunoprecipitation with the desired antibody. The supernatants (800 g) were then incubated with 2 g of anti-HA mouse monoclonal antibody (12CA5 clone, Roche Applied Science) or anti-phosphotyrosine antibody (clone 4G10, Upstate Biotechnology, Charlottesville, VA) and 50 l of protein Aagarose (Invitrogen) for 2 h at 4°C. Immunoprecipitates were washed four times with PBS (containing inhibitors for proteases and phosphatases) and then heated at 95°C in 2ϫ SDS sample buffer and resolved on SDS-polyacrylamide gels (10% polyacrylamide). Proteins from gels were electrotransferred onto nitrocellulose membranes (0.45-m pore size, Invitrogen) and subjected to immunoblotting with the indicated antibody. After incubation with the secondary antibody (HRP-conjugated anti-mouse, Amersham Biosciences) immunoreactive bands were visualized by ECL chemiluminescence (Amersham Biosciences), following the manufacturer's instructions.
For evaluation of tyrosine phosphorylation of total cellular proteins, cells were treated and processed as above. Where indicated, cells were incubated for 30 min with 100 M genistein before carbachol or OAG treatment. Aliquots (20 g) from each cell lysate were subjected to SDS-PAGE (10% polyacrylamide) electrophoresis and immunoblotted with anti-phosphotyrosine antibody 4G10.
Evaluation of Src Activation-TRPC3-HEK293 cells plated onto polylysine-coated 60-mm tissue culture dishes were washed two times in HBSS, equilibrated in the same solution for 20 min at room temperature, and then treated with either vehicle, carbachol (300 M), or OAG (100 M), either in the presence (2 mM) or absence of extracellular calcium (nominally Ca 2ϩ free) and in the presence of 5 M Gd 3ϩ . Where indicated, the protein kinase C inhibitor Gö6976 (1 M) was added to the incubation medium 15 min prior to OAG stimulation. The cells were then washed twice with ice-cold PBS and lysed as detailed above. The supernatants (800 g) were then incubated with 4 g of anti-Src mouse monoclonal antibody (clone GD11, Upstate Biotechnology) and 50 l of protein G-agarose (Calbiochem) for 2 h at 4°C. Immunoprecipitates were washed four times with PBS (containing inhibitors for proteases and phosphatases) and then processed as above for SDS-PAGE (10% polyacrylamide). Immunoblotting was performed using a specific antiphosphoSrc antibody (Calbiochem), which detects Src phosphorylated at Tyr-418 (16) . After incubation with the secondary antibody, immunoreactive phosphoSrc was detected by ECL chemiluminescence.
Materials-Fura-2-acetoxymethylester was from Molecular Probes Inc. Carbachol, OAG, Gö6976 (12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole), genistein, daidzein, erbstatin analogue, herbimycin, lavendustin A, bpV(phen) (bisperoxo(1,10-phenantroline)oxovanadate), AG1478, PP2 (4-amino-5-
, salicylate, piceatannol (3,4,3Ј,5Ј-tetrahydroxy-trans-stilbene), and sodium orthovanadate were purchased from Calbiochem. Recombinant human epidermal growth factor was from Upstate Biotechnology (Charlottesville, VA). The anti-chicken IgM antibody (clone M4) was from Southern Biotechnology Associates Inc. (Birmingham, AL). Nonidet P-40, sodium deoxycholate, sodium pyrophosphate, ␤-glycerophosphate, sodium fluoride, phenylmethylsulfonyl fluoride, CaCl 2 , BaCl 2 , and GdCl 2 were from Sigma. Complete® protease inhibitor tablets were from Roche Applied Science. All other reagents used were of analytical grade. Sources of antibodies and reagents for immunoprecipitation, electrophoresis, and immunoblotting are indicated in the corresponding methods sections.
RESULTS
We first evaluated the impact of inhibition of cellular tyrosine kinases on receptor-dependent TRPC3 activation by Fura-2 imaging of multiple single cells as indicated under "Materials and Methods" (and see Ref. 14) . As in previous work, 5 M Gd 3ϩ in the extracellular medium was used throughout these experiments to fully inhibit the endogenous capacitative calcium entry pathway (2, 17) . As shown in Fig. 1A , muscarinic stimulation of cells in Ca 2ϩ -free medium resulted in a transient release of Ca 2ϩ as a consequence of IP 3 -mediated mobilization from endogenous stores. Re-addition of Ca 2ϩ (2 mM) to the extracellular medium resulted in a robust Gd 3ϩ -insensitive Ca 2ϩ entry, indicating activation of TRPC3. Genistein caused a dose-dependent reduction in TRPC3 activation, with complete inhibition at 100 M genistein. The inactive genistein analogue, daidzein (100 M), did not inhibit (not shown). Erbstatin analogue, a tyrosine kinase inhibitor not chemically related to genistein (18) , also completely suppressed receptor-activation of TRPC3 (Fig. 1A) . At the concentrations used in this study, the tyrosine kinase inhibitors herbimycin (1 M) and lavendustin A (5 M) partially inhibited TRPC3-mediated Ca 2ϩ entry (not shown).
When TRPC3 is ectopically expressed in most cell lines, OAG-induced Gd 3ϩ -insensitive Ca 2ϩ entry constitutes a hallmark of TRPC3 activation (8) . We next examined the effect of tyrosine kinase inhibitors on OAG-induced activation of TRPC3. Both genistein (100 M) and erbstatin analogue (20 M) completely abrogated OAG-induced activation of TRPC3 (Fig. 1B) . Importantly, TRPC5, a member of the TRPC family, which has been shown to behave as a receptor-activated nonselective cation channel insensitive to OAG and store depletion (19) , was not affected by the tyrosine kinase inhibitors used here (not shown), thus ruling out potential nonspecific effects of the tyrosine kinase inhibitors such as plasma membrane depolarization. Finally, because further evidence that the effects of genistein result from inhibition of tyrosine kinases, treatment of TRPC3-expressing HEK293 cells with 200 M of the tyrosine phosphatase inhibitor bisperoxo(1,10-phenantroline)oxovanadate (bpV(phen)) (20) resulted in a partial recovery (ϳ30 -40%) from genistein inhibition of TRPC3 activation (Fig. 1C) . 2 Together, these observations strongly suggest that receptor-and OAG-dependent activation of TRPC3 requires tyrosine kinase activity.
To obtain preliminary insight into the putative identity of the tyrosine kinase/s involved in receptor-dependent activation of TRPC3, a panel of inhibitors specific for different families of tyrosine kinases was utilized. The potential roles of epidermal growth factor receptor-associated kinase activity, Syk and Srcfamily kinases, and the proline-rich tyrosine kinase Pyk2, all known to be activated downstream of stimulation of the G qcoupled muscarinic receptor (21) (22) (23) (24) (25) (26) , were evaluated.
Pre-treatment of HEK293 cells with the potent antagonist of the epidermal growth factor receptor, AG1478 (2 M (27)), did not affect the ability of muscarinic receptor stimulation to activate TRPC3-mediated calcium entry (not shown). Neither salicylate (20 mM), a compound reported as a specific inhibitor of Pyk2 (28), nor piceatannol (3,4,3Ј,5Ј-tetrahydroxy-trans-stilbene), a specific inhibitor for Syk (29, 30), a cytoplasmic protein-tyrosine kinase not belonging to the Src family, affected either receptor-or OAG-dependent activation of TRPC3, indicating that neither of these tyrosine kinases was required for signaling to TRPC3 (not shown). However, preincubation of HEK293 cells with the Src kinase-specific inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2 (31)) resulted in a dose-dependent reduction in both muscarinic receptor stimulated-and OAG-induced TRPC3-mediated cation entry, with almost complete inhibition at 5 M (Fig. 2) . This result suggests that an Src family kinase may be involved in both receptor and OAG activation of TRPC3.
To investigate more directly the involvement of Src, we determined the effect of transient expression of a kinase-dead dominant-negative mutant of human Src (DN-Src) into TRPC3-expressing HEK293 cells. This mutant carries a kinase inactivating mutation (Lys-295 3 Met) that results in complete suppression of Src kinase activity without altering its ability to interact with SH2 and/or SH3 binding partners (32) . As shown in Fig. 3 , both muscarinic receptor-and OAG-induced TRPC3-mediated cation entry were completely abrogated by DN-Src, whereas overexpression of the wild-type form of Src (WT-Src) had no such inhibitory effect. In parallel experiments, the endogenous store-operated pathway was assessed by observing thapsigargin-activated Ca 2ϩ entry (in the absence of Gd 3ϩ ). Significantly, the endogenous store-operated Ca 2ϩ entry pathway was not affected by DN-Src (not shown), ruling out alterations in membrane potential that might reduce the driving force for Ca 2ϩ entry. Also, DN-Src expression in HEK293 cells stably expressing TRPC3 tagged to GFP (TRPC3-GFP) showed that overexpression of the mutant did not affect either expression or the membrane targeting of the channel (not shown). Importantly, co-expression of WT-Src in TRPC3-HEK293 cells together with DN-Src partially rescued both agonist-and OAGdependent activation of TRPC3 (Fig. 3) . Expression of DN-Src and WT-Src was confirmed by Western analysis (not shown). Quantitation of the Western blots indicated that similar amounts of both forms were expressed and that the amount of protein expressed with the combination was approximately twice that for expression of each alone.
As an additional test to the hypothesis that Src activity is obligatory for signaling to TRPC3, we transiently expressed TRPC3 (together with the M5 muscarinic receptor) into SYF (Src Ϫ/Ϫ , Yes Ϫ/Ϫ , and Fyn Ϫ/Ϫ ) cells. SYF is a mouse embryo fibroblast cell line harboring functional null mutations in both alleles of the Src family protein-tyrosine kinases (33) . As shown in Fig. 4A , addition of 2 mM Ba 2ϩ to the extracellular bath resulted in the appearance of a significant Gd 3ϩ -insensitive cation entry in many transfected cells due to TRPC3 constitutive activity, because it was absent in cells transfected only with the M5 receptor (not shown). Subsequent activation of the muscarinic pathway resulted in a transient increase in intracellular Ca 2ϩ due to release from endogenous stores, but the rate of constitutive Ba 2ϩ entry, an indicator of TRPC3 activity, was not further increased. To minimize the cation entry due to TRPC3 constitutive activity, the Ba 2ϩ concentration was reduced to 0.5 mM. Under these conditions, constitutive Ba 2ϩ entry was minimized, and there was no evidence of carbacholstimulated TRPC3 activity (Fig. 4A) . Similarly, OAG failed to increase TRPC3-mediated Ba 2ϩ entry under these conditions (Fig. 4B) . That the lack of TRPC3 regulation in these cells was in fact due to the absence of Src expression was confirmed by two separate strategies. First, TRPC3 was transiently co-expressed with the muscarinic M5 receptor into YF (Yes Ϫ/Ϫ and Fyn Ϫ/Ϫ ) cells, which were obtained by stably reintroducing the wild-type form of Src into SYF cells (33) . As shown in Fig. 5 (A  and B) , challenging these cells with either carbachol or OAG significantly stimulated a Gd 3ϩ -insensitive cation entry that was absent in YF cells transfected with either the M5 receptor (Fig. 5A) or vector (pcDNA3, mock cells in Fig. 5B ) alone. Second, transiently co-expressing WT-Src into SYF cells together with TRPC3 and M5 receptor resulted in restitution of both receptor and OAG activation of the channel (Fig. 5, C  and D) .
The findings to this point indicate a clear obligatory role for active Src kinase in the mechanism for activation of TRPC3 channels. Tyrosine phosphorylation events are known to occur downstream of both GPCR-or RTK-activated pathways, and we confirmed that treatment of TRPC3-expressing HEK293 cells with either carbachol or OAG increased total tyrosine phosphorylation of cellular proteins, and this was blocked by genistein (not shown). We next sought to determine whether this tyrosine kinase activation resulted in tyrosine phosphorylation of TRPC3 and/or activation of Src. HEK293 cells stably expressing HA-epitope-tagged TRPC3 (13) were exposed for 10 min to either vehicle, the muscarinic agonist carbachol (300 M), OAG (100 M), or epidermal growth factor (EGF, 150 ng/ml). After treatment, cells were lysed and tyrosine phosphorylation of TRPC3 was evaluated by anti-phosphotyrosine immunoblotting the corresponding anti-HA immunoprecipitates (Fig. 6A) . We found no detectable phosphotyrosine signal under these experimental conditions. The reverse protocol, i.e. by anti-HA immunoblotting of anti-phosphotyrosine immunoprecipitates, also resulted in a negative result (not shown). We next measured Src activation by immunoblotting using a specific anti-phosphoSrc antibody, which specifically detects Src autophosphorylation at Tyr-418, a process indicative of Src activation (16) . We confirmed that Src was significantly activated following stimulation of the muscarinic pathway (Fig.  6B, lane 2) . Furthermore, consistent with the pharmacological data indicating a role for Src in OAG-dependent activation of TRPC3, OAG also caused activation of Src (Fig. 6B, lane 3) . However, neither carbachol nor OAG were able to induce activation of Src when extracellular calcium was omitted (Fig. 6B,  lanes 5-8) . Also, preincubation with the PKC inhibitor Gö6976 (1 M) almost completely reduced the ability of the DAG analogue to induce activation of Src (Fig. 6B, lane 4) , consistent with a PKC-mediated mechanism (34). These results indicated that carbachol-and OAG-dependent activation of Src is unlikely to be causally related to their ability to activate TRPC3, a process known to be independent of both extracellular calcium and PKC activity. Because Src family kinases may associate with and regulate effector proteins through tyrosine phosphorylation-independent interactions (35, 36), we sought evidence for association of TRPC3 with Src by co-immunoprecipitation. However, the results from co-immunoprecipitation experiments with both anti-HA and anti-Src antibodies were essentially negative, providing no evidence for physical association of the channel with Src (not shown).
We next addressed the question as to whether activation of Src could activate TRPC3 in the absence of agonist stimulation of DAG formation. Two approaches were used. First, TRPC3-expressing HEK293 cells were transfected with a constitutively active form of avian Src (CA-Src), and the constitutive activity of TRPC3 (12, 37) was evaluated and compared with that from both mock-and DN-Src-transfected cells. Ba 2ϩ (10 mM) was used as a surrogate for Ca 2ϩ , and the initial rate (first 2 min following Ba 2ϩ addition) of Ba 2ϩ entry was calculated (17) . Neither DN-Src (n ϭ 53) nor CA-Src (n ϭ 70) significantly altered TRPC3 constitutive activity (0.065 Ϯ 0.006 and 0.060 Ϯ 0.007 ratio units per min, for DN-Src and CA-Src, respectively) compared with that of mock (n ϭ 41) or non-transfected (n ϭ 46) cells (0.050 Ϯ 0.007 and 0.056 Ϯ 0.008 ratio units per min, respectively), indicating that active Src by itself was not able to activate the channel. The failure of DN-Src to diminish constitutive activity is consistent with the observation that DN-Src does not influence the expression or targeting of GFP-tagged TRPC3. Thus, because TRPC3 is clearly expressed and divalent cation-permeable channels are clearly present in the plasma membrane, this indicates that inhibition of Src activity prevents the activation mechanism of TRPC3, rather than altering the expression or basic permeation properties of the channels. Expression of the different Src mutants under our experimental conditions was confirmed by immunoblot (not shown).
A second approach to investigating the ability of Src to act on the channels independently involved use of a PLC␥2-deficient DT40 B lymphocyte cell line (PLC␥-KO DT40). These cells respond to B cell receptor (BCR) stimulation with activation of several tyrosine kinases, including Src protein-tyrosine kinases, but they are unable to generate IP 3 and DAG because they lack the phosphoinositide-specific PLC␥2 normally coupled to BCR activation (38, 39) . Transient expression of human TRPC3 in the wild-type DT40 cell line under appropriate conditions produces a channel that can be activated through either BCR stimulation or muscarinic receptor stimulation (15, 40) . In the experiments shown in Fig. 7, TRPC3 was transiently expressed in PLC␥-KO DT40 cells together with EYFP, and TRPC3-dependent Ba 2ϩ entry was evaluated. As expected, BCR stimulation of PLC␥-KO DT40 cells did not lead to Ca 2ϩ release from endogenous stores. BCR stimulation did not result in activation of TRPC3 (Fig. 7A, dotted trace) , in contrast with the efficient receptor-dependent activation of the channel when expressed in wild-type DT40 cells (data not shown and Ref. 15 ). These results indicated an absolute requirement of PLC␥ expression for BCR-dependent activation of TRPC3, most likely due to the requirement for PLC-dependent DAG generation for channel activity. More importantly, because Src activation is known to be normal in these cells, this result clearly shows that Src activation per se is not sufficient to activate TRPC3 channels. In support of this interpretation, carbachol stimulation of PLC␥-KO DT40 cells transiently co-transfected with the G q / PLC␤-coupled M5 muscarinic receptor and TRPC3, resulted in rapid IP 3 -induced release of Ca 2ϩ from stores followed by activation of TRPC3-mediated Ba 2ϩ entry (Fig. 7A, solid trace) , which was not observed in cells transfected with the M5 receptor alone (not shown). Additionally, as in TRPC3-expressing WT-DT40 cells (not shown, but see Fig. 5A in Ref. 15) , 100 M OAG significantly stimulated TRPC3-mediated Ca 2ϩ influx in PLC␥-KO DT40 cells (Fig. 7B) , whereas there was no effect of the DAG analogue on cation entry in mock-transfected cells. As in TRPC3-expressing HEK293 cells, both muscarinic and OAG activation of the channel in PLC␥-KO DT40 cells were completely blocked by pre-treatment with genistein (100 M) and erbstatin analogue (20 M; not shown). These results, together with those derived from TRPC3-HEK293 cells transiently expressing DN-Src and CA-Src, indicate that, although Src kinase activity appears to be absolutely necessary for channel activation, it is not sufficient in the absence of a DAG stimulus to cause channel activation.
DISCUSSION
Despite being one of the most extensively studied members of the canonical TRP subfamily, the precise signaling mechanism underlying TRPC3 activation and regulation remains uncertain. In many cell types, ectopic expression of TRPC3 produces a receptor-activated channel that can also be activated by exogenous application of membrane-permeant diacylglycerols (i.e. OAG). Activation by diacylglycerols is also a characteristic of the other members of the subfamily, TRPC6 and TRPC7 (8, 9) , and provides a potential mechanism for activation of these channels by PLC-linked receptors, independently of IP 3 and Ca 2ϩ store depletion. Although DAG generation through stimulation of either GPCRs or RTKs is currently widely accepted as a mechanism for TRPC3 activation, little is known about additional signaling pathways downstream of receptor stimulation involved in regulation of TRPC3 activity. Despite the existence of multiple potential phosphorylation sites in the TRPC3 primary sequence, there are very few studies specifically addressing the role of kinases in TRPC3 activity. Recent studies provided evidence that PKC (14, 41) and protein kinase G negatively regulate TRPC3 (42) . By using HEK293 cells stably expressing TRPC3 we found that the non-receptor tyrosine kinase Src is absolutely required for signaling to TRPC3, whether through receptor activation, or through application of OAG. Several lines of evidence support this concept. First, pretreatment of the cells with a specific inhibitor of Src, but not inhibitors of other tyrosine kinases, abrogated both receptor-and OAG-dependent activation of TRPC3. Second, transient expression of a dominant-negative form of Src (DN-Src) into TRPC3-HEK293 cells completely suppressed both receptor-and OAG-dependent TRPC3 activation. The endogenous store-operated pathway was not affected by DN-Src, indicating that the requirement for Src activity was specific for signaling to TRPC3. Note that this finding is inconsistent with the conclusion drawn by other investigators that Src plays a role in the store-operated pathway (43) (44) (45) . That DN-Src was in fact exerting a genuine dominant-negative action by competing out endogenous Src was confirmed by rescuing the response by concomitantly overexpressing the wild-type form of Src. Third, expression of TRPC3 into SYF cells (Src Ϫ/Ϫ , Yes Ϫ/Ϫ , and Fyn Ϫ/Ϫ ) resulted in a channel with the expected constitutive activity for TRPC3 but devoid of regulation by either receptor activation or OAG. However, when TRPC3 was transiently expressed into YF (Yes Ϫ/Ϫ and Fyn Ϫ/Ϫ ) cells, which do express Src (33), or when WT-Src and TRPC3 were coexpressed into SYF cells, receptor and OAG activation of TRPC3 was in both instances restored. These findings strongly support the concept of an obligatory role for Src activity for signaling to TRPC3.
Then, a more fundamental question arises: having established that Src kinase activity is absolutely required for TRPC3 activation, is it sufficient to activate the channel in the absence of DAG production? The evidence indicates that it is not. First, a constitutively active form of Src caused no significant activation of TRPC3. Second, expression of TRPC3 in a PLC␥2-deficient DT40 cell line resulted in a channel unresponsive to BCR stimulation. BCR stimulation of these cells results in normal activation of Src family tyrosine kinases, but there is no receptordependent generation of either IP 3 or DAG due to the lack of PLC␥2 (38, 39) . Together, these findings indicate that, although Src clearly has an obligatory role in TRPC3 regulation, it is not sufficient to regulate the channel in the absence of a DAG stimulus. On the other hand, the data also clearly show that DAG cannot be acting by simply interacting, alone, with TRPC3 channels. Rather, a concerted role of both diacylglycerol and Src seems to be necessary for TRPC3 activation, perhaps through a mechanism involving Src-dependent phosphorylation and/or recruitment of an as yet unknown accessory/regulatory protein within the vicinity of TRPC3. The action of Src does not appear to involve direct or indirect tyrosine phosphorylation of TRPC3 protein. However, we cannot absolutely rule out that some direct phosphorylation of TRPC3 might occur that might be transient and of modest stoichiometry and that might be undetectable by the anti-phosphotyrosine immunoblotting technique used here. Also, immunoprecipitation of TRPC3 failed to bring down detectable Src, and immunoprecipitation of Src failed to bring down detectable TRPC3, indicating that, if the two proteins physically interact in situ, the interaction is very labile. Additional studies, including in vitro analysis of channel protein phosphorylation and protein interactions, might be needed to specifically address this issue.
Patterson et al. (46) reported the failure of B-cell receptor or muscarinic receptor stimulation to activate entry in DT40 PLC␥2-deficient cells. This they interpreted as being indicative of a coupling, lipase-independent role of PLC␥ in agonist-dependent cation entry regulation. However, our experiments showing the inability of BCR stimulation to activate TRPC3 when expressed in the PLC␥2-deficient DT40 cell line indicate a requirement for PLC-dependent DAG generation for channel activity (8, 14, 40) . This is supported by the finding that stimulation of the Gq/PLC␤-coupled muscarinic receptor pathway or challenging the cells with OAG, efficiently activated TRPC3-mediated cation entry in PLC␥-KO DT40 cells, i.e. irrespectively of the status of PLC␥ expression.
A recent report described evidence for the Src family kinase Fyn having a role in EGF-dependent regulation of TRPC6, a close structural relative of TRPC3 (47) . By overexpressing both Fyn and TRPC6, these authors showed association of Fyn with TRPC6 and that Fyn phosphorylated the channel in an in vitro kinase assay. In contrast, in a previous study by Hassock et al. (48) endogenous TRPC6 in human platelets challenged with thrombin was found to be a substrate for cyclic AMP-dependent protein kinase but not for tyrosine kinases. Differences in channel protein level when both the channel and the kinase are overexpressed in a heterologous system (47) compared with those found under native conditions (48) , may in part account for this discrepancy. An increasing body of evidence implicates different kinases in regulation of ion channel function in the greater TRP superfamily. For example, PKC and protein kinase A modulate TRPV1 activity by direct channel phosphorylation (49) , whereas Src appears to be involved in regulation of both TRPM7 (50) and TRPV4 (51) . Thus, protein phosphorylation in general, and Src family tyrosine kinases in particular, are emerging as critical regulatory elements in the signaling mechanisms to TRP superfamily channels.
